Jeffrey (Jeff) W. Sherman, MD, FACP, has more than 30 years of experience in the biopharmaceutical industry. He was most recently the Chief Medical Officer and Executive Vice President at Horizon Therapeutics until its acquisition by Amgen. Dr. Sherman also served on the Board of Directors of Strongbridge prior to its acquisition by Xeris Pharmaceuticals, Inc in 2021. Additionally, Dr. Sherman served previously on the Board of Directors of the Biotechnology Innovation Organization (BIO), Larimar Therapeutics and of Sorriso Pharmaceuticals, Inc. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and on the Board of Advisors of the Center for Information and Study on Clinical Research Participation. He previously held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC/Pharmacia Corporation, and BristolMyers Squibb, and is a past board chair of the Drug Information Association.
Dr. Sherman received a B.A. in Biology from Lake Forest College and earned his M.D. from the Rosalind Franklin University of Medicine and Science/The Chicago Medical School. Dr. Sherman completed internship and residency programs at Northwestern University Feinberg School of Medicine, where he currently serves as an adjunct assistant professor, and a fellowship program at the University of California, San Francisco.
What is Jeffrey W. Sherman's net worth?
The estimated net worth of Jeffrey W. Sherman is at least $1.57 million as of August 28th, 2025. Sherman owns 219,188 shares of Xeris Biopharma stock worth more than $1,571,578 as of December 14th. This net worth approximation does not reflect any other assets that Sherman may own. Learn More about Jeffrey W. Sherman's net worth.
How do I contact Jeffrey W. Sherman?
Has Jeffrey W. Sherman been buying or selling shares of Xeris Biopharma?
Jeffrey W. Sherman has not been actively trading shares of Xeris Biopharma during the past quarter. Most recently, Jeffrey W. Sherman sold 42,232 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a transaction totalling $334,477.44. Following the completion of the sale, the director now directly owns 219,188 shares of the company's stock, valued at $1,735,968.96. Learn More on Jeffrey W. Sherman's trading history.
Who are Xeris Biopharma's active insiders?
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 8 times. They sold a total of 304,308 shares worth more than $2,181,194.23. The most recent insider tranaction occured on December, 1st when insider Beth Hecht sold 16,667 shares worth more than $116,835.67. Insiders at Xeris Biopharma own 4.6% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 12/1/2025.
